Lindbrook Capital LLC Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Lindbrook Capital LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,145 shares of the biopharmaceutical company’s stock after selling 14 shares during the quarter. Lindbrook Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $1,204,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $26,000. Sachetta LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at $28,000. Lynx Investment Advisory bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $33,000. Finally, Family Firm Inc. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on REGN. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,092.62.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $828.42 on Friday. The firm has a market capitalization of $91.04 billion, a P/E ratio of 20.50, a PEG ratio of 3.12 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52 week low of $783.57 and a 52 week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average price of $1,021.70 and a 200 day moving average price of $1,036.38.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.